Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Ease the symptoms of a UC flare, such as diarrhea, abdominal pain, and fever using expert-backed tips, and learn when to seek ...

Researchers at the University of Michigan Health Rogel Cancer Center discovered a new mechanism for eliminating one of the main side effects of immunotherapy treatment: colitis. Immunotherapy is used ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...

A new drug for treating a type of inflammatory bowel disease (IBD) has been given the go-ahead by the Food and Drug Administration. On Friday, the FDA approved Pfizer’s etrasimod, branded as Velsipity ...

Learn how prebiotics, or foods with compounds that support a healthy balance of gut bacteria (microbiome), may benefit people ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Real-world data show distinct determinants of health-related quality of life in Crohn’s disease and ulcerative colitis, ...